SCHEMBL3300337

SCHEMBL3300337

Cc1cc(Nc2ccnc(Nc3ccc(S(=O)(=O)N4CCC(C(O)c5cccnc5)CC4)cc3)n2)ccc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 2/20 0.42
CHUK O15111 2/20 0.42
HTT P42858 1/20 0.42
CDK2 P24941 2/20 0.41
CDK4 P11802 1/20 0.41
CCNE1 P24864 1/20 0.41
JAK2 O60674 1/20 0.40
JAK3 P52333 1/20 0.40
NAMPT P43490 3/20 0.40
CYP2C9 P11712 1/20 0.39
CA2 P00918 1/20 0.39
TP53 P04637 2/20 0.38
MAPT P10636 2/20 0.38
SYK P43405 1/20 0.38
RAB9A P51151 1/20 0.38
CYP11B1 P15538 2/20 0.38
CYP11B2 P19099 2/20 0.38
PIK3CD O00329 1/20 0.38
PIK3C2G O75747 1/20 0.38
PIK3CG P48736 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13392293 1.00 IKBKB (0.42) IKBKBCHUKHTTCDK2CDK4
SCHEMBL13392369 0.93 CDK4 (0.44) IKBKBCHUKHTTCDK2CDK4
SCHEMBL13392300 0.93 IKBKB (0.49) IKBKBCHUKHTTCDK2CDK4
SCHEMBL3306811 0.93 IKBKB (0.49) IKBKBCHUKHTTCDK2CDK4
SCHEMBL13392092 0.92 IKBKB (0.44) IKBKBCHUKCDK2CDK4CCNE1
SCHEMBL3295362 0.92 IKBKB (0.44) IKBKBCHUKCDK2CDK4CCNE1
SCHEMBL3301585 0.90 RAB9A (0.47) IKBKBHTTNAMPTCYP2C9CA2
SCHEMBL13392203 0.90 RAB9A (0.47) IKBKBHTTNAMPTCYP2C9CA2
SCHEMBL3298041 0.89 IKBKB (0.43) IKBKBCHUKCDK2CDK4CCNE1
SCHEMBL13392089 0.89 IKBKB (0.43) IKBKBCHUKCDK2CDK4CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS CHUK, IKBKB, IKBKE IKBKB 2/4885CHUK 1/4885HTT 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.